The state of PAT in the pharmaceutical industry

In a Pavilion Technologies survey, major manufacturers share details and insights regarding process analytical technology (PAT). The survey, conducted in 2004, asked leading pharmaceutical companies about their approaches to the Food and Drug Administration's PAT initiatives. Pavilion wanted to assess how and to what degree the pharmaceutical industry was taking advantage of the opportunities presented by PAT. It received feedback from 18 pharmaceutical manufacturers—12 in the U.S. and six in Europe. Read the results in this 2004 white paper.

Respondents were, for the most part, positive about PAT and its potential to effect change. "The FDA has recognized that the regulatory environment has been restrictive to bringing innovative technologies for analysis and for process control," said one principal scientist. "This is a very positive attempt to get rid of those restrictions. So it is essentially a golden opportunity to change the entire way we develop drugs." Read all the results in this white paper.

• Email This Page
• Print This Page